ISIN | LU2207278669 |
---|---|
Valorennummer | 114371863 |
Bloomberg Global ID | |
Fondsname | Kieger Impact Healthcare Fund Class R USD Accumulating |
Fondsanbieter |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Telefon: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
Fondsanbieter | Kieger AG |
Vertreter in der Schweiz |
ACOLIN Fund Services AG Zürich Telefon: +41 44 396 96 96 |
Distributor(en) | |
Anlagekategorie | Aktienfonds |
EFC-Kategorie | |
Anteilskategorie | Accumulation |
Domizilland | Luxemburg |
Konditionen bei der Ausgabe | keine Ausgabekommission und/oder Gebühren zugunsten des Fonds (Ausgabe erfolgt zum Inventarwert) |
Konditionen bei der Rücknahme | Keine Rücknahmekommission und/oder Gebühren zugunsten des Fonds (Rücknahme erfolgt zum Inventarwert) |
Investment-Strategie *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals ("SDGs"). No guarantee can be given that the investment objective will be achieved. |
Besonderheiten |
Aktueller Preis * | 87.18 USD | 13.03.2025 |
---|---|---|
Vorheriger Preis * | 88.13 USD | 12.03.2025 |
52 Wochen Hoch * | 97.97 USD | 16.07.2024 |
52 Wochen Tief * | 86.51 USD | 19.12.2024 |
NAV * | 87.18 USD | 13.03.2025 |
Ausgabepreis * | ||
Rücknahmepreis * | ||
Schlusskurs * | ||
Indikativer Minimalpreis | ||
Fondsvermögen *** | 87'320'896 | |
Anteilsklassevermögen *** | 1'839 | |
Trading Information SIX |
YTD-Performance | +0.48% |
31.12.2024 - 13.03.2025
31.12.2024 13.03.2025 |
---|---|---|
YTD-Performance (in CHF) | -2.31% |
31.12.2024 - 13.03.2025
31.12.2024 13.03.2025 |
1 Monat | -8.51% |
13.02.2025 - 13.03.2025
13.02.2025 13.03.2025 |
3 Monate | -2.84% |
13.12.2024 - 13.03.2025
13.12.2024 13.03.2025 |
6 Monate | -8.71% |
13.09.2024 - 13.03.2025
13.09.2024 13.03.2025 |
1 Jahr | -9.20% |
13.03.2024 - 13.03.2025
13.03.2024 13.03.2025 |
2 Jahre | -12.82% |
06.07.2023 - 13.03.2025
06.07.2023 13.03.2025 |
3 Jahre | - | - |
5 Jahre | - | - |
Kapitalbeteiligungsquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anteil am Gesamtvermögen in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immobilienquote in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Tandem Diabetes Care Inc | 4.17% | |
---|---|---|
Amplifon SpA Az nom Post Frazionamento | 3.74% | |
Hikma Pharmaceuticals PLC | 3.73% | |
Exact Sciences Corp | 3.72% | |
DexCom Inc | 3.66% | |
Gilead Sciences Inc | 3.63% | |
Centene Corp | 3.63% | |
Abbott Laboratories | 3.62% | |
GSK PLC | 3.57% | |
BioNTech SE ADR | 3.56% | |
Letzte Daten-Aktualisierung | 31.12.2024 |
TER *** | 2.22% |
---|---|
Datum TER *** | 30.09.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.00% |
Ongoing Charges *** | 2.22% |
SRRI ***
|
|
Datum SRRI *** | 28.02.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** |
Sustainable Investment |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |